



RECEIVED

AUG 31 2000

Attorney's Docket No.: 08262-017004

GAV 1646

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lipton
Serial No. : 08/346,910
Filed : November 30, 1994
Title : PROTEIN 68075 AND ITS USE FOR REGENERATING NERVE CELL PROCESSES

Art Unit : 1646
Examiner : Gucker, S.

Commissioner for Patents
Washington, D.C. 20231

AMENDMENT

In response to the action mailed May 24, 2000 (paper 23), please amend the application as follows:

In the Claims:

Please cancel claim 13 and replace with a new claim 14 to read:

14. An isolated fragment of nucleic acid comprising at least 20 contiguous bases of clone ATCC 97525, wherein said nucleic acid is able to selectively hybridize to nucleic acid encoding human MEF2C.--

REMARKS

Applicant appreciates the indication that claims 8 and 11-12 are in condition for allowance.¹

The only remaining claim, claim 13, was rejected under 35 U.S.C. §112, ¶1 with regard to the particular function of the claimed nucleic acid fragments – i.e. the fragments are said to

¹ Note that page 1 of paper 23 indicates that claims 8 & 10-11 are allowed. Since claim 10 has been canceled, and in view of ¶6 of the office action indicating that claims 8 and 11-12 are in condition for allowance, Applicant assumes the indication of allowance of claim 10 is an error.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

Signature

Typed or Printed Name of Person Signing Certificate

TECH CENTER 1600/2900

AUG 31 2000

RECEIVED